Celldex Therapeutics, Inc. (CLDX) Income Statement
CLDX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCLDX revenue and net income
Where CLDX's revenue goes
2025Each bar shows an amount and its share of revenue. CLDX kept −17,253.3% of revenue as net income.
CLDX profit margins
CLDX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −78.6% | −14.0% | −27.4% | −12.2% |
| Gross profit | — | — | — | +0.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CLDX quarterly EPS vs estimates
Celldex Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 9, 2026 (estimate $-1.02).
CLDX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M | $9.5M | $12.7M | $6.8M |
| Cost of revenue | $0 | $163.6M | $118.0M | $82.3M | $53.3M | $42.5M | $42.7M | $66.4M | $96.2M | $102.0M |
| Gross profit | $1.5M | −$156.5M | −$111.1M | −$79.9M | −$48.7M | −$35.1M | −$39.1M | −$56.9M | −$83.4M | −$95.2M |
| Research & development | $245.1M | $163.6M | $118.0M | $82.3M | $56.8M | $40.5M | $42.7M | $66.4M | $96.2M | $102.7M |
| Sales, general & admin | $43.8M | $38.5M | $30.9M | $27.2M | $20.5M | $14.5M | $15.4M | $19.3M | $25.0M | $36.0M |
| Total operating expenses | $288.9M | $38.5M | $43.4M | $35.3M | $22.6M | $28.2M | $15.9M | $99.5M | $38.1M | $37.7M |
| Operating income | −$287.4M | −$195.1M | −$154.5M | −$115.2M | −$71.2M | −$63.4M | −$55.0M | −$156.4M | −$121.5M | −$132.9M |
| Interest income | — | — | — | — | — | — | $4.2M | $4.5M | $4.2M | $4.4M |
| Interest expense | — | — | — | $2.9M | $112,000 | $18.8M | $0 | $151.1M | $16.0M | $0 |
| Income before taxes | −$258.8M | −$157.9M | −$141.4M | −$112.3M | −$70.7M | −$60.9M | −$50.9M | −$151.9M | −$117.3M | −$128.5M |
| Income taxes | — | −$157.9M | $2.8M | $10.5M | −$226,999 | −$1.2M | −$506,000 | −$765,000 | −$24.3M | −$8.8M |
| Net income | −$258.8M | −$157.9M | −$141.4M | −$112.3M | −$70.5M | −$59.8M | −$50.9M | −$151.2M | −$93.0M | −$128.5M |
| EBITDA | −$255.4M | −$154.7M | −$139.0M | −$104.2M | −$66.1M | −$45.6M | −$49.7M | −$72.6M | −$104.0M | −$124.4M |
| EPS (diluted) | −$3.89 | −$2.45 | −$2.91 | −$2.21 | −$1.56 | −$2.21 | −$3.63 | −$15.66 | −$13.20 | −$18.90 |
| Gross margin | 100.0% | −2,229.8% | −1,614.5% | −3,389.9% | −1,046.2% | −473.4% | −1,094.3% | −596.7% | −654.7% | −1,403.5% |
| Operating margin | −19,160.0% | −2,778.9% | −2,245.3% | −4,889.0% | −1,531.8% | −854.1% | −1,540.2% | −1,640.1% | −953.7% | −1,958.7% |
| Net margin | −17,253.3% | −2,248.8% | −2,054.8% | −4,765.6% | −1,516.0% | −805.9% | −1,424.0% | −1,585.1% | −730.1% | −1,894.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22,000 | $15,000 | $75,000 | $0 | $730,000 | $695,000 | $1.2M | $3.2M | $2.5M | $156,000 | $4.1M | $1.5M |
| Cost of revenue | $0 | $854,000 | $0 | $62.9M | $54.2M | $52.6M | $819,000 | $45.3M | $797,000 | $775,000 | $30.4M | $767,000 |
| Gross profit | $22,000 | −$839,000 | $75,000 | −$62.9M | −$53.5M | −$51.9M | $356,000 | −$42.1M | $1.7M | −$619,000 | −$26.3M | $750,000 |
| Research & development | $67.5M | $73.0M | $75.4M | $62.9M | $54.2M | $52.6M | $46.1M | $45.3M | $38.9M | $30.9M | $30.4M | $34.5M |
| Sales, general & admin | $13.1M | $11.4M | $11.9M | $10.7M | $10.4M | $10.8M | $10.3M | $10.1M | $9.1M | $9.1M | $8.8M | $8.2M |
| Total operating expenses | $80.6M | $83.6M | $87.3M | $10.7M | $10.4M | $10.8M | $56.4M | $10.1M | $48.0M | $40.0M | $21.3M | $42.0M |
| Operating income | −$80.6M | −$84.4M | −$87.2M | −$73.6M | −$63.9M | −$62.7M | −$56.0M | −$52.1M | −$46.3M | −$40.6M | −$47.6M | −$41.2M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $3.1M | — |
| Income before taxes | −$73.5M | −$78.7M | −$81.4M | −$67.0M | −$56.6M | −$53.8M | −$47.1M | −$42.1M | −$35.8M | −$32.8M | −$43.3M | −$38.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | $731,724 | $13.4M | −$3.0M |
| Net income | −$73.5M | −$78.7M | −$81.4M | −$67.0M | −$56.6M | −$53.8M | −$47.1M | −$42.1M | −$35.8M | −$32.8M | −$43.3M | −$38.3M |
| EBITDA | −$72.6M | −$77.8M | −$80.5M | −$66.2M | −$55.7M | −$52.9M | −$46.3M | −$41.3M | −$35.0M | −$32.0M | −$34.4M | −$37.5M |
| EPS (diluted) | −$0.94 | −$1.18 | −$1.22 | −$1.01 | −$0.85 | −$0.81 | −$0.71 | −$0.64 | −$0.54 | −$0.56 | −$0.83 | −$0.81 |
| Gross margin | 100.0% | −5,593.3% | 100.0% | — | −7,324.1% | −7,470.4% | 30.3% | −1,318.5% | 68.1% | −396.8% | −636.5% | 49.4% |
| Operating margin | −366,468.2% | −562,900.0% | −116,249.3% | — | −8,747.5% | −9,027.2% | −4,768.3% | −1,633.5% | −1,854.2% | −26,030.8% | −1,152.9% | −2,718.5% |
| Net margin | −334,104.5% | −524,566.7% | −108,480.0% | — | −7,753.4% | −7,740.4% | −4,007.8% | −1,320.0% | −1,434.8% | −21,030.8% | −1,048.3% | −2,522.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CLDX's financial statements (latest annual report filed February 25, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CLDX financial results
In fiscal year 2025 (ended December 31, 2025), Celldex Therapeutics reported revenue of $1.5 million, down 78.6% from the year before. It had a net loss of $258.8 million, a net profit margin of −17,253.3%. Diluted earnings per share came to −$3.89. Over five years revenue grew at an average rate of −27.4% a year.
See the CLDX stock overview for the latest quote and news, or the CLDX chart for price history and technical indicators.
CLDX income statement FAQ
What is Celldex Therapeutics's annual revenue?
Celldex Therapeutics reported total revenue of $1.5 million for fiscal year 2025, which ended on December 31, 2025. That was down 78.6% from $7.0 million the previous year.
Is Celldex Therapeutics profitable?
No. Celldex Therapeutics reported a net loss of $258.8 million in fiscal 2025, a net profit margin of −17,253.3%; its operating margin was −19,160.0%.
What is Celldex Therapeutics's gross margin?
Celldex Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Celldex Therapeutics kept $100 after the direct cost of its products and services.
How much does Celldex Therapeutics spend on research and development?
Celldex Therapeutics spent $245.1 million on research and development in fiscal 2025, 16,340.0% of revenue.
How fast is Celldex Therapeutics growing?
Revenue grew −27.4% a year on average over the last five fiscal years, from $7.4 million to $1.5 million.
What are Celldex Therapeutics's earnings per share?
Celldex Therapeutics earned $-3.89 per diluted share in fiscal 2025, compared with $-2.45 a year earlier.
When will Celldex Therapeutics report its next earnings?
Celldex Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes.
When does Celldex Therapeutics's fiscal year end?
Celldex Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 25, 2026.